Prednisolone Rhinosinusitis Efficacy Trial (PRET) study

Prednisolone Rhinosinusitis Efficacy Trial (PRET) study - PRET study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON33569

Enrollment

200

Registered

2008-07-11

Start date

2008-12-30

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rhinosinusitis sinusitis

Interventions

A 7 day course of 30 mg prednisolone per os once daily in addition to xylomethazoline nasal spray q8h for 7 days (usual care).

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with rhinosinusitis-like symptoms - according to the criteria of the guidelines of the Dutch College of General Practitioners - for at least 5 days;Age > 18 years

Exclusion criteria

Exclusion criteria: Fever > 38.5°C (measured by GP);> 2 episodes of RS in the previous 12 months;use of either nasal or oral corticosteroids in the previous 4 weeks;Contraindication for prednisolone treatment;Pregnancy;Previous ENT surgery for malignant disease

Design outcomes

Primary

Measure	Time frame
Resolution of facial pain at day 7.	—

Secondary

Measure	Time frame
Resumption of daily activities (school/work), health related quality of life and cost-effectiveness.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)